© Copyright Nostre Net
Market Highlights
Facial paralysis is a restriction of the facial movement due to nerve damage. Facial nerve paralysis is characterized by unilateral facial weakness. Some other symptoms include loss of taste, hyperacusis, and decreased salivation and tear secretion.
The global Facial Paralysis Treatment Market is expected to register a CAGR of 6.5% during the forecast period.
Key Players
Some of the key players in the Facial Paralysis Treatment Market are, Boston Scientific, BioControl Medical, Cerebomed, Cyberonics, Astellas Pharma Inc., Sucampo Pharmaceuticals, Inc., and Novartis AG, among others.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/5942
Segmentation
The global Facial Paralysis Treatment Market is segmented on the basis of treatment, diagnosis, type, and end-user.
On the basis of type, the market is segmented into, Ramsay Hunt Syndrome, Bell’s Palsy, and Lyme Disease.
On the basis of diagnosis, the market is segmented into electromyography, computerized tomography, and magnetic resonance imaging.
On the basis of treatment, the market is segmented into medications, physical therapy, and surgery.
On the basis of medication, the market is further sub-segmented into corticosteroids and antiviral drugs.
On the basis of end-user, the market is segmented into hospitals and clinics, specialty centers, and research centers.
Regional Analysis
The Americas dominates the global Facial Paralysis Treatment Market owing to increasing cardiovascular disorders, which eventually leads to the increasing patient population. Additionally, increasing cardiovascular disorder rate is likely to enhance the growth of facial paralysis in the North American region. According to the American Heart Association, 31% of the deaths in the U.S. were due to cardiovascular disorders. Similarly, in 2015, around USD 3.2 trillion were spend in healthcare expenditure in the U.S according to the Center for Disease Control and Prevention. Similarly, in 2015, 1.3% of the U.S. adults were diagnosed with inflammation of facial nerves.
Europe accounts for the second largest market due to increasing cardiovascular disorders and increasing infections. Additionally, the increasing government support and improving healthcare infrastructure along with increasing facial inflammations are driving the growth of the Facial Paralysis Treatment Market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. This increasing older population is likely to lead to the increasing patient population. These factors are likely to drive the growth of the Facial Paralysis Treatment Market.
Access Report @ https://www.marketresearchfuture.com/reports/facial-paralysis-market-5942
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The Wall